What is nuplazid?

What is Nuplazid and what is it used for?

Nuplazid, also known as pimavanserin, is an atypical antipsychotic medication developed by Acadia Pharmaceuticals [1]. It was first approved by the FDA in 2016 for the treatment of psychosis in patients with Parkinson's disease psychosis (PDP).

How does Nuplazid work?

Nuplazid works by targeting the serotonin 5-HT2A receptor, which is involved in the regulation of psychosis symptoms. It specifically binds to this receptor and reduces the activity of serotonin, thereby helping to alleviate psychotic symptoms in patients with PDP [2].

What are the benefits of Nuplazid?

Nuplazid has been shown to be effective in reducing psychotic symptoms in patients with PDP, including visual hallucinations and delusions. In clinical trials, patients treated with Nuplazid showed significant improvements in their symptoms compared to those receiving a placebo [1]. Additionally, Nuplazid has been associated with improved quality of life and reduced caregiver burden in these patients [3].

What are the side effects of Nuplazid?

Common side effects of Nuplazid include nausea, headache, dizziness, and falls. More serious side effects can include serotonin syndrome, a potentially life-threatening condition caused by excessive serotonin levels in the body [2]. Patients taking Nuplazid should be closely monitored by their healthcare provider for signs of serotonin syndrome.

Will Nuplazid's exclusivity expire soon?

The patent for Nuplazid is not expected to expire until 2034 [4], although exclusivity dates can change based on various factors, including market demand and patent litigation.

References:

[1] Acadia Pharmaceuticals. (2022). Nuplazid (pimavanserin) prescribing information.

[2] FDA. (2016). Pimavanserin.

[3] Citrome, L. L. (2018). The benefits of pimavanserin (Nuplazid) for Parkinson's disease psychosis. Journal of Clinical Psychopharmacology, 38(2), 147-152.

[4] DrugPatentWatch.com. (2022). Nuplazid (pimavanserin).